GB004 in Adult Subjects With Active Ulcerative Colitis
Status:
Completed
Trial end date:
2019-12-17
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, randomized, double-blind-, placebo-controlled, multi-center study to
evaluate the safety, tolerability, and PK of GB004 in adult subjects with active ulcerative
colitis. Target engagement and effect of GB004 on pharmacodynamic biomarkers will be
assessed.
Phase:
Phase 1
Details
Lead Sponsor:
GB004, Inc. GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.